Volume 12, Number 10—October 2006
Research
Active Surveillance of Candidemia, Australia
Sharon Chen*
, Monica Slavin†, Quoc Nguyen‡, Deborah Marriott‡, E. Geoffrey Playford§, David Ellis¶, Tania Sorrell*#, and the Australian Candidemia Study
, Monica Slavin†, Quoc Nguyen‡, Deborah Marriott‡, E. Geoffrey Playford§, David Ellis¶, Tania Sorrell*#, and the Australian Candidemia StudyTable 4
Multivariate predictors of death by candidemia 30 days after diagnosis, Australia, 2001–2004*
| Characteristic | OR | 95% CI | p value |
|---|---|---|---|
| Age >65 y | 3.0 | 2.0–4.3 | <0.001 |
| ICU stay | 3.2 | 2.1–5.0 | <0.001 |
| Corticosteroid therapy | 2.8 | 1.9–4.1 | <0.001 |
| Hemodialysis | 2.4 | 1.4–4.1 | 0.002 |
| Hyperalimentation | 1.7 | 1.1–2.5 | 0.006 |
| Antimicrobial drug use | 2.1 | 0.9–4.4 | 0.07 |
| Neutropenia | 2.2 | 1.3–3.6 | 0.002 |
| Sepsis present | 3.1 | 1.7–5.4 | <0.001 |
| Treatment with antifungal agent | 0.01 | 0.06–0.2 | <0.001 |
| Candida glabrata infection | 1.8 | 1.1–2.9 | 0.01 |
*Sixteen candidate variables were included in the final model. OR, odds ratio; CI, confidence interval; ICU, intensive care unit.
